{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T03:57:48Z","timestamp":1792468668369,"version":"4.5.0"},"reference-count":62,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2021,1,3]],"date-time":"2021-01-03T00:00:00Z","timestamp":1609632000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,1,3]],"date-time":"2021-01-03T00:00:00Z","timestamp":1609632000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100007914","name":"University of Texas Southwestern Medical Center","doi-asserted-by":"publisher","award":["Pollock family center for research in inflammatory bowel disease"],"award-info":[{"award-number":["Pollock family center for research in inflammatory bowel disease"]}],"id":[{"id":"10.13039\/100007914","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Clin Immunol"],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.1007\/s10875-020-00953-w","type":"journal-article","created":{"date-parts":[[2021,1,3]],"date-time":"2021-01-03T20:02:50Z","timestamp":1609704170000},"page":"285-293","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":39,"title":["Immune Dysfunction in Mendelian Disorders of POLA1 Deficiency"],"prefix":"10.1007","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9848-9187","authenticated-orcid":false,"given":"Petro","family":"Starokadomskyy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Escala Perez-Reyes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ezra","family":"Burstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,1,3]]},"reference":[{"issue":"2","key":"953_CR1","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1038\/nri3787","volume":"15","author":"F McNab","year":"2015","unstructured":"McNab F, Mayer-Barber K, Sher A, Wack A, O'Garra A. Type I interferons in infectious disease. Nat Rev Immunol. 2015;15(2):87\u2013103.","journal-title":"Nat Rev Immunol"},{"key":"953_CR2","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1146\/annurev-immunol-042718-041257","volume":"37","author":"C Uggenti","year":"2019","unstructured":"Uggenti C, Lepelley A, Crow YJ. Self-awareness: nucleic acid-driven inflammation and the type I interferonopathies. Annu Rev Immunol. 2019;37:247\u201367.","journal-title":"Annu Rev Immunol"},{"issue":"12","key":"953_CR3","doi-asserted-by":"publisher","first-page":"2527","DOI":"10.1084\/jem.20161596","volume":"213","author":"MP Rodero","year":"2016","unstructured":"Rodero MP, Crow YJ. Type I interferon-mediated monogenic autoinflammation: the type I interferonopathies, a conceptual overview. J Exp Med. 2016;213(12):2527\u201338.","journal-title":"J Exp Med"},{"issue":"4","key":"953_CR4","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1016\/j.cell.2008.06.032","volume":"134","author":"DB Stetson","year":"2008","unstructured":"Stetson DB, Ko JS, Heidmann T, Medzhitov R. Trex1 prevents cell-intrinsic initiation of autoimmunity. Cell. 2008;134(4):587\u201398.","journal-title":"Cell."},{"key":"953_CR5","doi-asserted-by":"crossref","unstructured":"Lim YW, Sanz LA, Xu X, Hartono SR, Chedin F. Genome-wide DNA hypomethylation and RNA:DNA hybrid accumulation in Aicardi\u2013Goutieres syndrome. eLife. 2015;4:e08007.","DOI":"10.7554\/eLife.08007"},{"key":"953_CR6","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1111\/j.1749-6632.2011.06220.x","volume":"1238","author":"YJ Crow","year":"2011","unstructured":"Crow YJ. Type I interferonopathies: a novel set of inborn errors of immunity. Ann N Y Acad Sci. 2011;1238:91\u20138.","journal-title":"Ann N Y Acad Sci"},{"issue":"4","key":"953_CR7","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1007\/s00281-015-0486-4","volume":"37","author":"A Brehm","year":"2015","unstructured":"Brehm A, Kruger E. Dysfunction in protein clearance by the proteasome: impact on autoinflammatory diseases. Semin Immunopathol. 2015;37(4):323\u201333.","journal-title":"Semin Immunopathol"},{"issue":"11","key":"953_CR8","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1038\/ng.2414","volume":"44","author":"GI Rice","year":"2012","unstructured":"Rice GI, Kasher PR, Forte GM, Mannion NM, Greenwood SM, Szynkiewicz M, et al. Mutations in ADAR1 cause Aicardi\u2013Goutieres syndrome associated with a type I interferon signature. Nat Genet. 2012;44(11):1243\u20138.","journal-title":"Nat Genet"},{"issue":"7","key":"953_CR9","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1038\/ng.373","volume":"41","author":"GI Rice","year":"2009","unstructured":"Rice GI, Bond J, Asipu A, Brunette RL, Manfield IW, Carr IM, et al. Mutations involved in Aicardi\u2013Goutieres syndrome implicate SAMHD1 as regulator of the innate immune response. Nat Genet. 2009;41(7):829\u201332.","journal-title":"Nat Genet"},{"issue":"3","key":"953_CR10","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1084\/jem.20151464","volume":"213","author":"V Pokatayev","year":"2016","unstructured":"Pokatayev V, Hasin N, Chon H, Cerritelli SM, Sakhuja K, Ward JM, et al. RNase H2 catalytic core Aicardi\u2013Goutieres syndrome-related mutant invokes cGAS-STING innate immune-sensing pathway in mice. J Exp Med. 2016;213(3):329\u201336.","journal-title":"J Exp Med"},{"issue":"1","key":"953_CR11","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1186\/s13023-019-1155-9","volume":"14","author":"R Kameli","year":"2019","unstructured":"Kameli R, Amanat M, Rezaei Z, Hosseionpour S, Nikbakht S, Alizadeh H, et al. RNASET2-deficient leukoencephalopathy mimicking congenital CMV infection and Aicardi\u2013Goutieres syndrome: a case report with a novel pathogenic variant. Orphanet J Rare Dis. 2019;14(1):184.","journal-title":"Orphanet J Rare Dis"},{"issue":"3","key":"953_CR12","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1007\/s10875-015-0147-3","volume":"35","author":"GI Rice","year":"2015","unstructured":"Rice GI, Rodero MP, Crow YJ. Human disease phenotypes associated with mutations in TREX1. J Clin Immunol. 2015;35(3):235\u201343.","journal-title":"J Clin Immunol"},{"issue":"5","key":"953_CR13","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1038\/ng.2933","volume":"46","author":"GI Rice","year":"2014","unstructured":"Rice GI, Del Toro Duany Y, Jenkinson EM, Forte GM, Anderson BH, Ariaudo G, et al. Gain-of-function mutations in IFIH1 cause a spectrum of human disease phenotypes associated with upregulated type I interferon signaling. Nat Genet. 2014;46(5):503\u20139.","journal-title":"Nat Genet"},{"key":"953_CR14","doi-asserted-by":"crossref","unstructured":"Uggenti C, Lepelley A, Depp M, Badrock AP, Rodero MP, El-Daher MT, et al. cGAS-mediated induction of type I interferon due to inborn errors of histone pre-mRNA processing. Nat Genet. 2020;52:1364\u20131372.","DOI":"10.1038\/s41588-020-00737-3"},{"key":"953_CR15","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/1546-0096-12-44","volume":"12","author":"A Belot","year":"2014","unstructured":"Belot A, Wassmer E, Twilt M, Lega JC, Zeef LA, Oojageer A, et al. Mutations in CECR1 associated with a neutrophil signature in peripheral blood. Pediatr Rheumatol Online J. 2014;12:44.","journal-title":"Pediatr Rheumatol Online J"},{"issue":"6","key":"953_CR16","doi-asserted-by":"publisher","first-page":"2016","DOI":"10.1016\/j.jaci.2016.12.957","volume":"139","author":"KL Del Bel","year":"2017","unstructured":"Del Bel KL, Ragotte RJ, Saferali A, Lee S, Vercauteren SM, Mostafavi SA, et al. JAK1 gain-of-function causes an autosomal dominant immune dysregulatory and hypereosinophilic syndrome. J Allergy Clin Immunol. 2017;139(6):2016\u201320 e5.","journal-title":"J Allergy Clin Immunol"},{"issue":"42","key":"953_CR17","doi-asserted-by":"publisher","first-page":"eaav7501","DOI":"10.1126\/sciimmunol.aav7501","volume":"4","author":"CJA Duncan","year":"2019","unstructured":"Duncan CJA, Thompson BJ, Chen R, Rice GI, Gothe F, Young DF, et al. Severe type I interferonopathy and unrestrained interferon signaling due to a homozygous germline mutation in STAT2. Sci Immunol. 2019;4(42):eaav7501.","journal-title":"Sci Immunol"},{"issue":"9","key":"953_CR18","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1038\/ni.2948","volume":"15","author":"SC Eckard","year":"2014","unstructured":"Eckard SC, Rice GI, Fabre A, Badens C, Gray EE, Hartley JL, et al. The SKIV2L RNA exosome limits activation of the RIG-I-like receptors. Nat Immunol. 2014;15(9):839\u201345.","journal-title":"Nat Immunol"},{"key":"953_CR19","doi-asserted-by":"publisher","first-page":"967","DOI":"10.3389\/fimmu.2020.00967","volume":"11","author":"M Erdos","year":"2020","unstructured":"Erdos M, Jakobicz E, Soltesz B, Toth B, Bata-Csorgo Z, Marodi L. Recurrent, Severe aphthous stomatitis and mucosal ulcers as primary manifestations of a novel STAT1 gain-of-function mutation. Front Immunol. 2020;11:967.","journal-title":"Front Immunol"},{"issue":"1","key":"953_CR20","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1007\/s10875-018-0572-1","volume":"39","author":"CR Ferreira","year":"2019","unstructured":"Ferreira CR, Crow YJ, Gahl WA, Gardner PJ, Goldbach-Mansky R, Hur S, et al. DDX58 and Classic Singleton\u2013Merten Syndrome. J Clin Immunol. 2019;39(1):75\u201380.","journal-title":"J Clin Immunol"},{"issue":"4","key":"953_CR21","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1136\/annrheumdis-2017-212401","volume":"77","author":"A Giannelou","year":"2018","unstructured":"Giannelou A, Wang H, Zhou Q, Park YH, Abu-Asab MS, Ylaya K, et al. Aberrant tRNA processing causes an autoinflammatory syndrome responsive to TNF inhibitors. Ann Rheum Dis. 2018;77(4):612\u20139.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"953_CR22","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/j.jaci.2017.10.030","volume":"142","author":"E Gul","year":"2018","unstructured":"Gul E, Sayar EH, Gungor B, Eroglu FK, Surucu N, Keles S, et al. Type I IFN-related NETosis in ataxia telangiectasia and Artemis deficiency. J Allergy Clin Immunol. 2018;142(1):246\u201357.","journal-title":"J Allergy Clin Immunol"},{"issue":"7","key":"953_CR23","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1084\/jem.20151529","volume":"213","author":"ME Meuwissen","year":"2016","unstructured":"Meuwissen ME, Schot R, Buta S, Oudesluijs G, Tinschert S, Speer SD, et al. Human USP18 deficiency underlies type 1 interferonopathy leading to severe pseudo-TORCH syndrome. J Exp Med. 2016;213(7):1163\u201374.","journal-title":"J Exp Med"},{"issue":"5","key":"953_CR24","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1038\/ni.3420","volume":"17","author":"I Meyts","year":"2016","unstructured":"Meyts I, Casanova JL. A human inborn error connects the \u03b1's. Nat Immunol. 2016;17(5):472\u20134.","journal-title":"Nat Immunol"},{"issue":"5","key":"953_CR25","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1016\/j.immuni.2015.11.001","volume":"43","author":"K Pestal","year":"2015","unstructured":"Pestal K, Funk CC, Snyder JM, Price ND, Treuting PM, Stetson DB. Isoforms of RNA-editing enzyme ADAR1 independently control nucleic acid sensor MDA5-driven autoimmunity and multi-organ development. Immunity. 2015;43(5):933\u201344.","journal-title":"Immunity."},{"issue":"3","key":"953_CR26","doi-asserted-by":"publisher","first-page":"e65","DOI":"10.1016\/j.chest.2016.02.682","volume":"150","author":"C Picard","year":"2016","unstructured":"Picard C, Thouvenin G, Kannengiesser C, Dubus JC, Jeremiah N, Rieux-Laucat F, et al. Severe pulmonary fibrosis as the first manifestation of interferonopathy (TMEM173 mutation). Chest. 2016;150(3):e65\u201371.","journal-title":"Chest."},{"issue":"1","key":"953_CR27","doi-asserted-by":"publisher","first-page":"2176","DOI":"10.1038\/s41467-017-01932-3","volume":"8","author":"MP Rodero","year":"2017","unstructured":"Rodero MP, Tesser A, Bartok E, Rice GI, Della Mina E, Depp M, et al. Type I interferon-mediated autoinflammation due to DNase II deficiency. Nat Commun. 2017;8(1):2176.","journal-title":"Nat Commun"},{"issue":"11","key":"953_CR28","doi-asserted-by":"publisher","first-page":"1474","DOI":"10.1093\/ecco-jcc\/jjz079","volume":"13","author":"L Sifuentes-Dominguez","year":"2019","unstructured":"Sifuentes-Dominguez L, Starokadomskyy P, Welch J, Gurram B, Park JY, Koduru P, et al. Mosaic tetrasomy 9p associated with inflammatory bowel disease. J Crohns Colitis. 2019;13(11):1474\u20138.","journal-title":"J Crohns Colitis"},{"issue":"5","key":"953_CR29","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1002\/art.40805","volume":"71","author":"K Meesilpavikkai","year":"2019","unstructured":"Meesilpavikkai K, Dik WA, Schrijver B, van Helden-Meeuwsen CG, Versnel MA, van Hagen PM, et al. Efficacy of baricitinib in the treatment of chilblains associated with Aicardi\u2013Goutieres syndrome, a type I interferonopathy. Arthritis Rheum. 2019;71(5):829\u201331.","journal-title":"Arthritis Rheum"},{"issue":"8","key":"953_CR30","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1007\/s10875-018-0563-2","volume":"38","author":"KE McLellan","year":"2018","unstructured":"McLellan KE, Martin N, Davidson JE, Cordeiro N, Oates BD, Neven B, et al. JAK 1\/2 Blockade in MDA5 gain-of-function. J Clin Immunol. 2018;38(8):844\u20136.","journal-title":"J Clin Immunol"},{"issue":"7","key":"953_CR31","doi-asserted-by":"publisher","first-page":"3041","DOI":"10.1172\/JCI98814","volume":"128","author":"GAM Sanchez","year":"2018","unstructured":"Sanchez GAM, Reinhardt A, Ramsey S, Wittkowski H, Hashkes PJ, Berkun Y, et al. JAK1\/2 inhibition with baricitinib in the treatment of autoinflammatory interferonopathies. J Clin Invest. 2018;128(7):3041\u201352.","journal-title":"J Clin Invest"},{"key":"953_CR32","doi-asserted-by":"crossref","unstructured":"Legeret C, Meyer BJ, Rovina A, Deigendesch N, Berger CT, Daikeler T, et al. JAK inhibition in a patient with X-linked reticulate pigmentary disorder. J Clin Immunol. 2020. Online ahead of print.","DOI":"10.1007\/s10875-020-00867-7"},{"key":"953_CR33","doi-asserted-by":"crossref","unstructured":"Baranovskiy AG, Tahirov TH. Elaborated action of the human primosome. Genes (Basel). 2017;8(2): 62.","DOI":"10.3390\/genes8020062"},{"issue":"23","key":"953_CR34","doi-asserted-by":"publisher","first-page":"14328","DOI":"10.1074\/jbc.M115.649954","volume":"290","author":"Y Suwa","year":"2015","unstructured":"Suwa Y, Gu J, Baranovskiy AG, Babayeva ND, Pavlov YI, Tahirov TH. Crystal structure of the human Pol alpha B subunit in complex with the C-terminal domain of the catalytic subunit. J Biol Chem. 2015;290(23):14328\u201337.","journal-title":"J Biol Chem"},{"key":"953_CR35","doi-asserted-by":"crossref","unstructured":"Starokadomskyy P, Gemelli T, Rios JJ, Xing C, Wang RC, Li H, et al. DNA polymerase-\u03b1 regulates the activation of type I interferons through cytosolic RNA:DNA synthesis. Nat Immunol. 2016;17(5):495\u2013504.","DOI":"10.1038\/ni.3409"},{"key":"953_CR36","doi-asserted-by":"crossref","unstructured":"Starokadomskyy P, Wilton KM, Krzewski K, Lopez A, Sifuentes-Dominguez L, Overlee B, et al. NK cell defects in X-linked pigmentary reticulate disorder. JCI Insight. 2019;4(21): e125688.","DOI":"10.1172\/jci.insight.125688"},{"issue":"5","key":"953_CR37","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1016\/j.ajhg.2019.03.006","volume":"104","author":"H Van Esch","year":"2019","unstructured":"Van Esch H, Colnaghi R, Freson K, Starokadomskyy P, Zankl A, Backx L, et al. Defective DNA polymerase alpha-Primase leads to X-linked intellectual disability associated with severe growth retardation, microcephaly, and hypogonadism. Am J Hum Genet. 2019;104(5):957\u201367.","journal-title":"Am J Hum Genet"},{"issue":"1","key":"953_CR38","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1002\/ajmg.1320100109","volume":"10","author":"MW Partington","year":"1981","unstructured":"Partington MW, Marriott PJ, Prentice RS, Cavaglia A, Simpson NE. Familial cutaneous amyloidosis with systemic manifestations in males. Am J Med Genet. 1981;10(1):65\u201375.","journal-title":"Am J Med Genet"},{"issue":"1","key":"953_CR39","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1002\/ajmg.1320320125","volume":"32","author":"MW Partington","year":"1989","unstructured":"Partington MW, Prentice RS. X-linked cutaneous amyloidosis: further clinical and pathological observations. Am J Med Genet. 1989;32(1):115\u20139.","journal-title":"Am J Med Genet"},{"issue":"2","key":"953_CR40","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1111\/j.1525-1470.2005.22206.x","volume":"22","author":"RC Anderson","year":"2005","unstructured":"Anderson RC, Zinn AR, Kim J, Carder KR. X-linked reticulate pigmentary disorder with systemic manifestations: report of a third family and literature review. Pediatr Dermatol. 2005;22(2):122\u20136.","journal-title":"Pediatr Dermatol"},{"issue":"1","key":"953_CR41","first-page":"102","volume":"18","author":"M Fernandez-Guarino","year":"2008","unstructured":"Fernandez-Guarino M, Torrelo A, Fernandez-Lorente M, Fraile G, Garcia-Sagredo JM, Jaen P. X-linked reticulate pigmentary disorder: report of a new family. Eur J Dermatol. 2008;18(1):102\u20133.","journal-title":"Eur J Dermatol"},{"issue":"5","key":"953_CR42","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1007\/s00439-008-0498-4","volume":"123","author":"LJ Jaeckle Santos","year":"2008","unstructured":"Jaeckle Santos LJ, Xing C, Barnes RB, Ades LC, Megarbane A, Vidal C, et al. Refined mapping of X-linked reticulate pigmentary disorder and sequencing of candidate genes. Hum Genet. 2008;123(5):469\u201376.","journal-title":"Hum Genet"},{"issue":"6","key":"953_CR43","doi-asserted-by":"publisher","first-page":"1414","DOI":"10.1002\/ajmg.a.35882","volume":"161","author":"L Pezzani","year":"2013","unstructured":"Pezzani L, Brena M, Callea M, Colombi M, Tadini G. X-linked reticulate pigmentary disorder with systemic manifestations: a new family and review of the literature. Am J Med Genet A. 2013;161(6):1414\u201320.","journal-title":"Am J Med Genet A"},{"issue":"5","key":"953_CR44","doi-asserted-by":"publisher","first-page":"e200","DOI":"10.1111\/bjd.15586","volume":"177","author":"P Starokadomskyy","year":"2017","unstructured":"Starokadomskyy P, Sifuentes-Dominguez L, Gemelli T, Zinn AR, Dossi MT, Mellado C, et al. Evolution of the skin manifestations of X-linked pigmentary reticulate disorder. Br J Dermatol. 2017;177(5):e200\u2013e1.","journal-title":"Br J Dermatol"},{"key":"953_CR45","doi-asserted-by":"crossref","unstructured":"Kim BS, Seo SH, Jung HD, Kwon KS, Kim MB. X-Linked reticulate pigmentary disorder in a female patient. Int J Dermatol. 2010;49:421\u20135.","DOI":"10.1111\/j.1365-4632.2010.04102.x"},{"issue":"1","key":"953_CR46","first-page":"85","volume":"16","author":"H M\u00e9garban\u00e9","year":"2005","unstructured":"M\u00e9garban\u00e9 H, Boehm N, Chouery E, Bernard R, Salem N, Halaby E, et al. X-linked reticulate pigmentary layer. Report of a new patient and demonstration of a skewed X-inactivation. Genet Couns. 2005;16(1):85\u20139.","journal-title":"Genet Couns"},{"issue":"6785","key":"953_CR47","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1038\/35013114","volume":"405","author":"A Smahi","year":"2000","unstructured":"Smahi A, Courtois G, Vabres P, Yamaoka S, Heuertz S, Munnich A, et al. Genomic rearrangement in NEMO impairs NF-\u03baB activation and is a cause of incontinentia pigmenti. The International Incontinentia Pigmenti (IP) Consortium. Nature. 2000;405(6785):466\u201372.","journal-title":"Nature."},{"issue":"4","key":"953_CR48","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1080\/03014460701723912","volume":"43","author":"G Fraile","year":"2008","unstructured":"Fraile G, Norman F, Reguero ME, Defargues V, Redondo C. Cryptogenic multifocal ulcerous stenosing enteritis (CMUSE) in a man with a diagnosis of X-linked reticulate pigmentary disorder (PDR). Scand J Gastroenterol. 2008;43(4):506\u201310.","journal-title":"Scand J Gastroenterol"},{"issue":"1","key":"953_CR49","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1002\/ajmg.1320520115","volume":"52","author":"AK Gedeon","year":"1994","unstructured":"Gedeon AK, Mulley JC, Kozman H, Donnelly A, Partington MW. Localisation of the gene for X-linked reticulate pigmentary disorder with systemic manifestations (PDR), previously known as X-linked cutaneous amyloidosis. Am J Med Genet. 1994;52(1):75\u20138.","journal-title":"Am J Med Genet"},{"key":"953_CR50","doi-asserted-by":"publisher","first-page":"1520","DOI":"10.1101\/gad.340190.120","volume":"34","author":"DA Parry","year":"2020","unstructured":"Parry DA, Tamayo-Orrego L, Carroll P, Marsh JA, Greene P, Murina O, et al. PRIM1 deficiency causes a distinctive primordial dwarfism syndrome. Genes Dev. 2020;34:1520\u201333.","journal-title":"Genes Dev"},{"key":"953_CR51","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.sbi.2018.06.003","volume":"53","author":"R Jain","year":"2018","unstructured":"Jain R, Aggarwal AK, Rechkoblit O. Eukaryotic DNA polymerases. Curr Opin Struct Biol. 2018;53:77\u201387.","journal-title":"Curr Opin Struct Biol"},{"key":"953_CR52","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1016\/j.ebiom.2016.02.025","volume":"6","author":"M Ebbo","year":"2016","unstructured":"Ebbo M, Gerard L, Carpentier S, Vely F, Cypowyj S, Farnarier C, et al. Low circulating natural killer cell counts are associated with severe disease in patients with common variable immunodeficiency. EBioMedicine. 2016;6:222\u201330.","journal-title":"EBioMedicine."},{"issue":"3","key":"953_CR53","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1016\/j.jaci.2013.07.020","volume":"132","author":"JS Orange","year":"2013","unstructured":"Orange JS. Natural killer cell deficiency. J Allergy Clin Immunol. 2013;132(3):515\u201325.","journal-title":"J Allergy Clin Immunol"},{"issue":"10","key":"953_CR54","doi-asserted-by":"publisher","first-page":"5272","DOI":"10.1172\/JCI134966","volume":"130","author":"EM Mace","year":"2020","unstructured":"Mace EM, Paust S, Conte MI, Baxley RM, Schmit MM, Patil SL, et al. Human NK cell deficiency as a result of biallelic mutations in MCM10. J Clin Invest. 2020;130(10):5272\u201386.","journal-title":"J Clin Invest"},{"issue":"3","key":"953_CR55","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1172\/JCI60224","volume":"122","author":"CR Hughes","year":"2012","unstructured":"Hughes CR, Guasti L, Meimaridou E, Chuang CH, Schimenti JC, King PJ, et al. MCM4 mutation causes adrenal failure, short stature, and natural killer cell deficiency in humans. J Clin Invest. 2012;122(3):814\u201320.","journal-title":"J Clin Invest"},{"issue":"3","key":"953_CR56","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1172\/JCI61014","volume":"122","author":"L Gineau","year":"2012","unstructured":"Gineau L, Cognet C, Kara N, Lach FP, Dunne J, Veturi U, et al. Partial MCM4 deficiency in patients with growth retardation, adrenal insufficiency, and natural killer cell deficiency. J Clin Invest. 2012;122(3):821\u201332.","journal-title":"J Clin Invest"},{"issue":"5","key":"953_CR57","doi-asserted-by":"publisher","first-page":"1991","DOI":"10.1172\/JCI90727","volume":"127","author":"J Cottineau","year":"2017","unstructured":"Cottineau J, Kottemann MC, Lach FP, Kang YH, Vely F, Deenick EK, et al. Inherited GINS1 deficiency underlies growth retardation along with neutropenia and NK cell deficiency. J Clin Invest. 2017;127(5):1991\u20132006.","journal-title":"J Clin Invest"},{"issue":"3","key":"953_CR58","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1136\/annrheumdis-2018-214037","volume":"78","author":"C Briand","year":"2019","unstructured":"Briand C, Fremond ML, Bessis D, Carbasse A, Rice GI, Bondet V, et al. Efficacy of JAK1\/2 inhibition in the treatment of chilblain lupus due to TREX1 deficiency. Ann Rheum Dis. 2019;78(3):431\u20133.","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"953_CR59","doi-asserted-by":"publisher","first-page":"1752","DOI":"10.1016\/j.jaci.2016.07.015","volume":"138","author":"ML Fremond","year":"2016","unstructured":"Fremond ML, Rodero MP, Jeremiah N, Belot A, Jeziorski E, Duffy D, et al. Efficacy of the Janus kinase 1\/2 inhibitor ruxolitinib in the treatment of vasculopathy associated with TMEM173-activating mutations in 3 children. J Allergy Clin Immunol. 2016;138(6):1752\u20135.","journal-title":"J Allergy Clin Immunol"},{"issue":"6","key":"953_CR60","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1212\/WNL.0000000000004921","volume":"90","author":"K Kothur","year":"2018","unstructured":"Kothur K, Bandodkar S, Chu S, Wienholt L, Johnson A, Barclay P, et al. An open-label trial of JAK 1\/2 blockade in progressive IFIH1-associated neuroinflammation. Neurology. 2018;90(6):289\u201391.","journal-title":"Neurology."},{"issue":"5","key":"953_CR61","doi-asserted-by":"publisher","first-page":"e79","DOI":"10.1038\/cti.2016.26","volume":"5","author":"S Oon","year":"2016","unstructured":"Oon S, Wilson NJ, Wicks I. Targeted therapeutics in SLE: emerging strategies to modulate the interferon pathway. Clin Transl Immunology. 2016;5(5):e79.","journal-title":"Clin Transl Immunology"},{"issue":"6","key":"953_CR62","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1038\/clpt.2013.35","volume":"93","author":"B Wang","year":"2013","unstructured":"Wang B, Higgs BW, Chang L, Vainshtein I, Liu Z, Streicher K, et al. Pharmacogenomics and translational simulations to bridge indications for an anti-interferon-alpha receptor antibody. Clin Pharmacol Ther. 2013;93(6):483\u201392.","journal-title":"Clin Pharmacol Ther"}],"container-title":["Journal of Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10875-020-00953-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10875-020-00953-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10875-020-00953-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,3]],"date-time":"2021-02-03T21:15:32Z","timestamp":1612386932000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10875-020-00953-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,3]]},"references-count":62,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,2]]}},"alternative-id":["953"],"URL":"https:\/\/doi.org\/10.1007\/s10875-020-00953-w","relation":{},"ISSN":["0271-9142","1573-2592"],"issn-type":[{"value":"0271-9142","type":"print"},{"value":"1573-2592","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,3]]},"assertion":[{"value":"3 November 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 December 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 January 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}